医药稳健科研股策略:年化收益率（32.57%）
本策略精选医药生物行业中研发投入高、净利润快速增长、估值合理的优质股票。通过量化财务指标，筛选出具备持续成长潜力的标的，并定期轮动调仓，力求在医药行业中获取稳健收益。
概要
核心指标
- 累计收益率: 67.12%
- 年化收益率: 32.57%
- 基准收益率: 7.89%
- 阿尔法: 0.3
- 夏普比率: 1.06
- 最大回撤: 22.06%
源码
查看AI策略代码
绩效
持仓详情
|
当日收盘价 | 当日市值 | 浮动收益/浮动收益率
|
|||||
|---|---|---|---|---|---|---|---|
| 2025-08-01 | 亚宝药业(600351.SH) | 5.8502682259687 | 74330 | 63 | 7.95 | 590923.5 | 156073.06/35.891% |
| 2025-08-01 | 国药现代(600420.SH) | 10.128008357566 | 45308 | 63 | 11.39 | 516058.12 | 57178.32/12.46% |
| 2025-08-01 | 浙江医药(600216.SH) | 13.725877665798 | 34290 | 93 | 15.94 | 546582.6 | 75922.25/16.131% |
| 2025-07-31 | 亚宝药业(600351.SH) | 5.8502682259687 | 74330 | 62 | 7.5 | 557475 | 122624.56/28.199% |
| 2025-07-31 | 国药现代(600420.SH) | 10.128008357566 | 45308 | 62 | 11.47 | 519682.76 | 60802.96/13.25% |
| 2025-07-31 | 浙江医药(600216.SH) | 13.725877665798 | 34290 | 92 | 15.92 | 545896.8 | 75236.45/15.985% |
| 2025-07-30 | 亚宝药业(600351.SH) | 5.8502682259687 | 74330 | 61 | 7.19 | 534432.7 | 99582.26/22.9% |
| 2025-07-30 | 国药现代(600420.SH) | 10.128008357566 | 45308 | 61 | 11.58 | 524666.64 | 65786.84/14.336% |
| 2025-07-30 | 浙江医药(600216.SH) | 13.725877665798 | 34290 | 91 | 16.41 | 562698.9 | 92038.55/19.555% |
| 2025-07-29 | 亚宝药业(600351.SH) | 5.8502682259687 | 76730 | 60 | 7.16 | 549386.8 | 100495.72/22.388% |
交易详情
| 2025-07-30 | 浙江医药(600216.SH) | 买 | 600 | 15.43 | 9258 | ¥5 | 0 |
| 2025-07-30 | 国药现代(600420.SH) | 买 | 200 | 11.39 | 2278 | ¥5 | 0 |
| 2025-07-30 | 亚宝药业(600351.SH) | 卖 | -2400 | 7.22 | -17328 | ¥22.53 | 3287.36 |
| 2025-07-23 | 浙江医药(600216.SH) | 买 | 700 | 15.1 | 10570 | ¥5 | 0 |
| 2025-07-23 | 国药现代(600420.SH) | 买 | 100 | 11.11 | 1111 | ¥5 | 0 |
| 2025-07-23 | 亚宝药业(600351.SH) | 卖 | -1800 | 6.63 | -11934 | ¥16.93 | 1403.52 |
| 2025-07-21 | 浙江医药(600216.SH) | 买 | 790 | 15.08 | -0.8 | ¥0 | 0 |
| 2025-07-18 | 国药现代(600420.SH) | 买 | 808 | 10.94 | -0.48 | ¥0 | 0 |
| 2025-07-16 | 浙江医药(600216.SH) | 买 | 100 | 15.04 | 1504 | ¥5 | 0 |
| 2025-07-16 | 亚宝药业(600351.SH) | 买 | 100 | 6.25 | 625 | ¥5 | 0 |
